Shenzhen Absen Optoelectronic (300389.SZ) plans to launch an employee stock ownership plan in 2025, with an estimated number of shares held at 5.3 million.
Abbott (300389.SZ) disclosed the 2025 employee stock ownership plan (draft), the company's employee stock ownership plan...
Shenzhen Absen Optoelectronic (300389.SZ) disclosed the 2025 employee shareholding plan (draft). The total number of employees participating in the company's employee shareholding plan will not exceed 72, including 11 directors (excluding independent directors), supervisors, and senior management personnel, and no more than 61 other employees.
The funds for this employee shareholding plan will come from the special incentive fund extracted by the company from 2025 to 2028. This incentive fund will be used entirely for the employee shareholding plan to purchase and hold company stocks. The upper limit for the amount of the incentive fund extracted for this employee shareholding plan is 60 million yuan. The employee shareholding plan uses "shares" as the subscription unit, with each share being 1 yuan. The total number of shares in the employee shareholding plan will not exceed 60 million shares. Based on the closing price of 11.32 yuan per share on January 7, 2025, the employee shareholding plan can hold approximately 5.300353 million shares of the target stock.
The duration of the employee shareholding plan is 72 months, calculated from the date of approval of the employee shareholding plan draft by the company's shareholder meeting and the completion of the last purchase of target stocks as announced by the company.
Related Articles

HK Stock Market Move | KEYMED BIO-B(02162) rose by over 7%, Goldman Sachs said that Sipokiba monoclonal antibody is expected to lay the foundation for the company's valuation.

Show resilience! European companies are "immune" to US tariffs, and are expected to achieve double-digit profit growth next year.

FIRST SHANGHAI: Maintains "Buy" rating on Zhuzhou CRRC Times Electric (03898) with a target price of 55 Hong Kong dollars.
HK Stock Market Move | KEYMED BIO-B(02162) rose by over 7%, Goldman Sachs said that Sipokiba monoclonal antibody is expected to lay the foundation for the company's valuation.

Show resilience! European companies are "immune" to US tariffs, and are expected to achieve double-digit profit growth next year.

FIRST SHANGHAI: Maintains "Buy" rating on Zhuzhou CRRC Times Electric (03898) with a target price of 55 Hong Kong dollars.

RECOMMEND

First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025

Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025

Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025


